Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
L'entreprise
L'entreprise
Notre histoire
Notre équipe
Carrières
Partenaires
NEWS
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Accès
Affaires médicales
Accès aux patients
Contactez les affaires médicales
NEWS
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Ressources
Ressources
Dans la presse
Communiqués de presse
Ressources pour les patients
FAQ
NEWS
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Investisseurs
Investisseurs
Aperçu pour les investisseurs
Informations financières
Évènements
NEWS
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Oups ! Une erreur s'est produite lors de l'envoi du formulaire.
Merci ! Votre candidature a été reçue !
Oups ! Une erreur s'est produite lors de l'envoi du formulaire.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable, locally advanced pMMR or dMMR colon cancer: results from the UNICORN trial by GONO
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO- GI)
January 25, 2025
,
Ghelardi et al.
Colorectal (CRC)
Lisez maintenant
Téléchargez maintenant
View Poster
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Neoadjuvant Botensilimab (BOT) Plus Balstilimab (BAL) in Resectable Mismatch Repair Proficient (pMMR) and Deficient (dMMR) Colorectal Cancer (CRC)
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO- GI)
January 25, 2025
,
Hissong et al.
Colorectal (CRC)
Lisez maintenant
Téléchargez maintenant
View Poster
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of Botensilimab With or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO-GI)
January 25, 2025
,
Fakih, et al.
Colorectal (CRC)
Lisez maintenant
Téléchargez maintenant
View Publication
AGENT-797 (Allogeneic iNKT Cell Therapy)
TPS 515: A phase II study of agenT-797 (invariant natural killer T cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO-GI)